Grail Inc. Faces Investigation Amid Disappointing Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2026
0mins
Source: Globenewswire
Grail Inc. shares fell 13.22% as the stock hit a 20-day low, reflecting investor concerns following negative trial results and ongoing investigations.
The NHS-Galleri trial did not meet its primary endpoint, leading to a significant drop in Grail's stock price. Additionally, Robbins Geller Rudman & Dowd LLP has launched an investigation into potential securities law violations involving Grail, further compounding investor anxiety about the company's future. The combination of disappointing trial outcomes and legal scrutiny has raised alarms among investors, prompting them to reassess their positions in the stock.
The implications of these developments are profound, as the ongoing investigation and trial failures may hinder Grail's ability to secure future funding and partnerships. Investors are advised to closely monitor the situation as it unfolds, given the potential for increased volatility in Grail's stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 68.950
Low
38.00
Averages
60.86
High
83.71
Current: 68.950
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc., targeting investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that GRAIL failed to demonstrate a significant reduction in Stage III-IV cancers in the NHS Galleri trial and did not provide detailed trial results, potentially hiding trends that indicated a longer timeline was necessary to achieve the primary endpoint, impacting investor decisions.
- Stock Price Impact: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a significant drop in the company's stock price, reflecting market disappointment with the trial results.
- Investor Action: Investors must apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out for more information.
See More
Investors Alert: Class Action Lawsuits Against Badger Meter and Others
- Lawsuit Overview: A shareholder class action lawsuit against Badger Meter, Inc. alleges that the company made materially false or misleading statements from April 18, 2024, to April 16, 2026, regarding customer orders and demand, potentially leading to investor losses.
- Legal Consultation Info: Affected investors are encouraged to contact Holzer & Holzer law firm for legal advice at 888-508-6832 or visit their website for more information, indicating the firm's commitment to supporting victims.
- Grail, Inc. Lawsuit: The class action lawsuit against Grail, Inc. alleges that the company failed to disclose material facts related to its NHS-Galleri trial between May 13, 2025, and February 19, 2026, impacting investor decisions.
- PicS N.V. Lawsuit: The shareholder class action against PicS N.V. claims that misleading statements were made in the offering documents during its January 2026 IPO regarding credit evaluation procedures, potentially causing investor losses.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of distorting its financial results from 2024 to 2026 by prematurely recognizing customer orders, which concealed weakening demand and could adversely affect future revenue performance, impacting investor confidence.
- PicS Lawsuit: PicS N.V. faces allegations of failing to disclose deficiencies in its credit evaluation procedures in its offering documents, leading to a reclassification of approximately R$590 million in exposures and an additional R$88 million expected credit loss, potentially undermining investor trust in the company's financial health.
- Verra Mobility Lawsuit: Verra Mobility Corporation is accused of not disclosing the critical nature of its contract renewal with Avis for its growth plans in Commercial Services, which could severely impact its 2026 performance expectations and influence investor decisions.
- Grail Lawsuit: Grail, Inc. is alleged to have misrepresented management's confidence in trial results, potentially misleading investors regarding the achievability of primary endpoints, which could affect the company's future market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled the market regarding its NHS-Galleri trial's effectiveness in reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view of the trial's prospects.
- Market Reaction Impact: As the market learned the truth about GRAIL, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
GRAIL, Inc. Shareholder Class Action Filed Over Alleged Misstatements
- Class Action Initiated: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased GRAIL, Inc. (NASDAQ: GRAL) stock between May 13, 2025, and February 19, 2026, alleging that the company made materially false and misleading statements, resulting in artificially inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to the defendants' misrepresentations, GRAIL's stock traded at inflated prices, leading to significant losses for investors when the truth was revealed, highlighting serious concerns regarding the company's financial stability and growth prospects.
- Call to Action: Investors are encouraged to promptly submit a form to join the lawsuit, and those wishing to serve as lead plaintiff must file papers by August 4, 2026, indicating the firm's commitment to protecting shareholder rights.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its expertise and influence in the securities litigation field.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock plummeted by 50.55% on February 19, 2026, due to the failure to meet the primary endpoint of the NHS-Galleri trial, dropping from $101.53 to $50.21 per share, severely undermining investor confidence and potentially affecting future financing capabilities.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit on behalf of GRAIL investors, accusing the company and its executives of misleading investors regarding the NHS-Galleri cancer trial, potentially violating federal securities laws, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed that the NHS-Galleri trial was designed for three years of screening to achieve its primary endpoint, but the complaint alleges that this timeframe was insufficient to demonstrate effectiveness, which could damage the company's reputation in the early cancer detection market.
- Legal Consequences: The lawsuit could result in GRAIL facing substantial liability for damages, and if unsuccessful, it may impact its financial condition and market position, prompting investors to monitor developments closely to assess potential losses.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc., targeting investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that GRAIL failed to demonstrate a significant reduction in Stage III-IV cancers in the NHS Galleri trial and did not provide detailed trial results, potentially hiding trends that indicated a longer timeline was necessary to achieve the primary endpoint, impacting investor decisions.
- Stock Price Impact: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a significant drop in the company's stock price, reflecting market disappointment with the trial results.
- Investor Action: Investors must apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out for more information.
See More
Investors Alert: Class Action Lawsuits Against Badger Meter and Others
- Lawsuit Overview: A shareholder class action lawsuit against Badger Meter, Inc. alleges that the company made materially false or misleading statements from April 18, 2024, to April 16, 2026, regarding customer orders and demand, potentially leading to investor losses.
- Legal Consultation Info: Affected investors are encouraged to contact Holzer & Holzer law firm for legal advice at 888-508-6832 or visit their website for more information, indicating the firm's commitment to supporting victims.
- Grail, Inc. Lawsuit: The class action lawsuit against Grail, Inc. alleges that the company failed to disclose material facts related to its NHS-Galleri trial between May 13, 2025, and February 19, 2026, impacting investor decisions.
- PicS N.V. Lawsuit: The shareholder class action against PicS N.V. claims that misleading statements were made in the offering documents during its January 2026 IPO regarding credit evaluation procedures, potentially causing investor losses.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of distorting its financial results from 2024 to 2026 by prematurely recognizing customer orders, which concealed weakening demand and could adversely affect future revenue performance, impacting investor confidence.
- PicS Lawsuit: PicS N.V. faces allegations of failing to disclose deficiencies in its credit evaluation procedures in its offering documents, leading to a reclassification of approximately R$590 million in exposures and an additional R$88 million expected credit loss, potentially undermining investor trust in the company's financial health.
- Verra Mobility Lawsuit: Verra Mobility Corporation is accused of not disclosing the critical nature of its contract renewal with Avis for its growth plans in Commercial Services, which could severely impact its 2026 performance expectations and influence investor decisions.
- Grail Lawsuit: Grail, Inc. is alleged to have misrepresented management's confidence in trial results, potentially misleading investors regarding the achievability of primary endpoints, which could affect the company's future market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled the market regarding its NHS-Galleri trial's effectiveness in reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view of the trial's prospects.
- Market Reaction Impact: As the market learned the truth about GRAIL, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
GRAIL, Inc. Shareholder Class Action Filed Over Alleged Misstatements
- Class Action Initiated: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased GRAIL, Inc. (NASDAQ: GRAL) stock between May 13, 2025, and February 19, 2026, alleging that the company made materially false and misleading statements, resulting in artificially inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to the defendants' misrepresentations, GRAIL's stock traded at inflated prices, leading to significant losses for investors when the truth was revealed, highlighting serious concerns regarding the company's financial stability and growth prospects.
- Call to Action: Investors are encouraged to promptly submit a form to join the lawsuit, and those wishing to serve as lead plaintiff must file papers by August 4, 2026, indicating the firm's commitment to protecting shareholder rights.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its expertise and influence in the securities litigation field.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock plummeted by 50.55% on February 19, 2026, due to the failure to meet the primary endpoint of the NHS-Galleri trial, dropping from $101.53 to $50.21 per share, severely undermining investor confidence and potentially affecting future financing capabilities.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit on behalf of GRAIL investors, accusing the company and its executives of misleading investors regarding the NHS-Galleri cancer trial, potentially violating federal securities laws, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed that the NHS-Galleri trial was designed for three years of screening to achieve its primary endpoint, but the complaint alleges that this timeframe was insufficient to demonstrate effectiveness, which could damage the company's reputation in the early cancer detection market.
- Legal Consequences: The lawsuit could result in GRAIL facing substantial liability for damages, and if unsuccessful, it may impact its financial condition and market position, prompting investors to monitor developments closely to assess potential losses.
See More
